The US Food and Drug Administration (FDA) has cleared Novaliq’s Investigational New Drug (IND) application for NOV05, ...

From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua ...

For optometrists, 2026 provides ample opportunity to continue the charge in advancements in dry eye, artificial intelligence ...

For patients for whom surgery is indicated but who are opposed to undergoing glaucoma surgery, he may suggest a different ...

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and ...

Data estimates the prevalence of glaucoma currently is almost 50% higher than previously estimated and over 1.6 million ...

Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...

Nanoscope Therapeutics has received Pioneering Regenerative Medical Product (Sakigake) and Orphan Drug designations for ...

The January 31, 2026, conference in Mainz, Germany, will focus on advances in optic neuropathy diagnosis, artificial ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

Management of geographic atrophy (GA) has changed with the introduction of retinal therapies aimed at slowing disease ...

Analysis of 20 years of data highlights differences in reimbursement trends across ophthalmology subspecialties and practice ...